GB202104635D0 - Methods and compositions for identifying and treating GCN2-dependent cancers - Google Patents
Methods and compositions for identifying and treating GCN2-dependent cancersInfo
- Publication number
- GB202104635D0 GB202104635D0 GBGB2104635.4A GB202104635A GB202104635D0 GB 202104635 D0 GB202104635 D0 GB 202104635D0 GB 202104635 A GB202104635 A GB 202104635A GB 202104635 D0 GB202104635 D0 GB 202104635D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- gcn2
- identifying
- compositions
- treating
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2104635.4A GB202104635D0 (en) | 2021-03-31 | 2021-03-31 | Methods and compositions for identifying and treating GCN2-dependent cancers |
PCT/GB2022/050825 WO2022208107A1 (en) | 2021-03-31 | 2022-03-31 | Methods and compositions for identifying and treating gcn2-dependent cancers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2104635.4A GB202104635D0 (en) | 2021-03-31 | 2021-03-31 | Methods and compositions for identifying and treating GCN2-dependent cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202104635D0 true GB202104635D0 (en) | 2021-05-12 |
Family
ID=75783639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2104635.4A Ceased GB202104635D0 (en) | 2021-03-31 | 2021-03-31 | Methods and compositions for identifying and treating GCN2-dependent cancers |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202104635D0 (en) |
WO (1) | WO2022208107A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018030466A1 (en) | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | Heterocyclic compound |
US20190233411A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
US20190233425A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10648983B2 (en) * | 2016-01-08 | 2020-05-12 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
WO2018024608A2 (en) * | 2016-08-03 | 2018-02-08 | Cbmed Gmbh Center For Biomarker Research In Medicine | Antitumor compounds and tumor diagnosis |
GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
CN112522401B (en) * | 2020-11-16 | 2021-09-24 | 北京大学人民医院 | Application of TOX3 gene overexpression as liver cancer prognosis marker |
-
2021
- 2021-03-31 GB GBGB2104635.4A patent/GB202104635D0/en not_active Ceased
-
2022
- 2022-03-31 WO PCT/GB2022/050825 patent/WO2022208107A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018030466A1 (en) | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | Heterocyclic compound |
US20190233411A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
US20190233425A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
Non-Patent Citations (35)
Title |
---|
BRAZEAUROSSE, ACS MED CHEM LETT., vol. 5, no. 4, 2014, pages 282 - 283 |
CIARDIELLO ET AL., ANNALS OF ONCOLOGY, vol. 31, no. 10, 2020, pages 1336 - 1349 |
DONG ET AL., MOL CELL, vol. 6, 2000, pages 269 - 279 |
DONG ET AL., MOLECULAR CELL, vol. 6, 2000, pages 269 - 279 |
DURINCK ET AL.: "BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis", BIOINFORMATICS, vol. 21, 2005, pages 3439 - 3440 |
FRIEDMAN ET AL., J STAT SOFTW, vol. 33, 2010, pages 1 - 22 |
FUJIMOTO, J. ET AL., ACS MED. CHEM. LETT., vol. 10, no. 1, 2019, pages 1498 - 1503 |
GARLAND, CURRENT BIOLOGY, vol. 24, 2014, pages R60 - 61 |
GU ET AL., BIOINFORMATICS, vol. 32, 2016, pages 2847 - 2849 |
HANAHANWEINBERG, CELL, vol. 144, 2011, pages 646 - 674 |
HANZELMANN ET AL., BMC BIOINFORMATICS, vol. 14, no. 7, 2013 |
HARDING ET AL., MOL CELL, vol. 11, 2003, pages 619 - 633 |
HARDING ET AL., MOLECULAR CELL, vol. 11, 2003, pages 619 - 633 |
HUYNH ET AL., BIOMOLECULES, vol. 9, no. 11, 2019, pages 743 |
JAIN ET AL., SCIENCE, vol. 336, 2012, pages 1040 - 1044 |
KATO ET AL., MOL. PHARM., vol. 98, no. 6, 2020, pages 669 - 676 |
LISTANMORE, COLD SPRING HARBOR PROTOCOLS, 2019 |
LOAIZA ET AL., BIOMATERIALS, vol. 183, 2018, pages 102 - 113 |
LOVE ET AL., GENOME BIOL, vol. 15, 2014, pages 550 |
LU ET AL., J. BIOMED. SCI., vol. 27, no. 1, 2020, Retrieved from the Internet <URL:http://doi.org/10.1186/s12929-019-0592> |
M. E. RITCHIE ET AL.: "limma powers differential expression analyses for RNA-sequencing and microarray studies", NUCLEIC ACIDS RES, vol. 43, 2015, pages e47 |
MOREAU ET AL., BLOOD, vol. 120, 2012, pages 947 - 959 |
NAKAMURA ET AL., PNAS, vol. 115, no. 33, 2018, pages E7776 - E7785 |
NATURE GENETICS, vol. 49, no. 12, pages 1779 - 1784 |
OBENG ET AL., BLOOD, vol. 107, 2006, pages 4907 - 4916 |
OU ET AL., J CLIN PHARMACOL, vol. 57, 2017, pages 663 - 677 |
PAPADOPOULOS ET AL., J CLIN ONCOL, vol. 33, 2015, pages 732 - 739 |
PARZYCH ET AL., ONCOGENE, vol. 38, 2019, pages 3216 - 3231 |
PETROVA ET AL., ONCOGENESIS, vol. 7, 2018, pages 10 |
POUYSSEGUR ET AL., NATURE, vol. 441, 2006, pages 437 - 443 |
RIO ET AL.: "RNA: A Laboratory Manual", 2011, COLD SPRING HARBOR LABORATORY PRESS |
S. DURINCKP. T. SPELLMANE. BIRNEYW. HUBER: "Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt", NAT PROTOC, vol. 4, 2009, pages 1184 - 1191 |
SAAVEDRA-GARCIA ET AL., AMERICAN JOURNAL OF PHYSIOLOGY: CELL PHYSIOLOGY, vol. 318, 2020, pages C451 - C462 |
SHAUGHNESSY, JR. ET AL., BLOOD, vol. 118, 2011, pages 3512 - 3524 |
SONESON ET AL., FLOOORES, vol. 4, 2015, pages 1521 |
Also Published As
Publication number | Publication date |
---|---|
WO2022208107A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288914A (en) | Compositions and methods for treating cancer | |
IL286350A (en) | Compositions and methods for treating cancer | |
EP4149547A4 (en) | Compositions and methods for treating cancer | |
ZA202104870B (en) | Methods and compositions for treating cancer | |
IL300067A (en) | Compositions and methods for treatment of cancers | |
IL287982A (en) | Compositions and methods for treating cancer | |
EP4097486A4 (en) | Compositions and methods for treating ceacam positive cancers | |
SG11202109336UA (en) | Methods and compositions for treating cancer | |
IL285886A (en) | Compositions and methods for treating laminopathies | |
EP4110822A4 (en) | Compositions and methods for treating cancer | |
IL286153A (en) | Methods and compositions for treating cancer | |
EP4100028A4 (en) | Compositions and methods for treating mesothelin positive cancers | |
IL309662A (en) | Compositions and methods for treating cancers | |
EP4127722A4 (en) | Methods and compositions for treating cancer | |
IL312846A (en) | Methods and compositions for treating cancer | |
IL312844A (en) | Methods and compositions for treating cancer | |
EP3959199A4 (en) | Compositions and methods for treating ras-mutant cancers | |
IL309120A (en) | Methods and compositions for treating cancer | |
IL309071A (en) | Methods and compositions for treating cancer | |
IL304400A (en) | Compositions and methods for preventing tumors and cancer | |
PT4058474T (en) | Compositions and methods for treating egfr positive cancers | |
EP4149508A4 (en) | Compositions and methods for treating cancer | |
EP4243835A4 (en) | Compositions and methods for treating solid cancer | |
EP4118122A4 (en) | Methods and compositions for identifying and treating glutaminase inhibitor-sensitive cancers | |
IL285036A (en) | Methods and compositions for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |